RxDoctor Payments Data

Dawn Caster, MD

Nephrology · Louisville, KYNPI 1659402287

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 34.3% of the total. Reporting peaked in 2024 at $59,953 and has fallen 54.6% since, to $27,233 in 2025. Among nephrology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$192,810in general payments, 2019–2025

Across 179 payments — averaging $1077.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$66K
  • GSK$46K
  • Aurinia Pharma U.S., Inc.$33K
  • Travere Therapeutics, Inc.$21K
  • Novartis$15K
  • Apellis Pharmaceuticals, Inc.$9K
  • plus $3K from 7 others
$709,207in research payments, 2019–2025

Across 157 payments — averaging $4517.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$283K
  • Travere Therapeutics, Inc.$269K
  • AstraZeneca$152K
  • Mallinckrodt Enterprises LLC$3K
  • Mallinckrodt Hospital Products Inc.$3K

What the payments were for

  • Consulting fees$72,58038%
  • Speaking & faculty fees$96,44050%
  • Grants$1,0391%
  • Travel & lodging$17,2899%
  • Food & beverage$5,3093%
  • Education$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,810 in reported general payments places this provider in the 95th percentile of 165 nephrology providers in Kentucky.

See all nephrology providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,395
Medicare patients
118
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mycophenolate Mofetil21$4,003
Mycophenolic AcidMycophenolate Sodium17$2,509
Amlodipine Besylate51$495
Carvedilol42$480
Prednisone35$347
Losartan Potassium55$339
Furosemide43$304
Potassium Chloride19$276
Benazepril Hcl13$183
Metoprolol Tartrate17$101
Allopurinol16$100
Hydralazine Hcl11$98
Calcitriol11$82
Lisinopril24$53
Bumetanide11$41

Paid to pharmacies, not to this prescriber.

Other nephrology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →